A provider-focused briefing on Agrylin (Anagrelide) availability, shortage history, prescribing implications, and tools for managing patient access in 2026.
For hematologists, oncologists, and other clinicians managing patients with myeloproliferative neoplasms, Anagrelide (Agrylin) availability has been a recurring concern. While the formal shortage that peaked in 2018-2019 has been resolved, sporadic supply disruptions and pharmacy stocking gaps continue to affect patient access to this important platelet-reducing agent.
This briefing provides an up-to-date overview of Agrylin's supply status, prescribing implications, cost considerations, and practical tools to help ensure your patients maintain uninterrupted therapy.
Understanding the history of Agrylin supply issues provides important context for current availability challenges:
The supply landscape for Anagrelide has several direct implications for prescribing practice:
Agrylin carries a boxed warning regarding abrupt discontinuation. Sudden cessation or substantial dose reduction can cause rapid platelet count elevation, potentially leading to cerebral infarction and other fatal thrombotic events. This makes supply interruptions particularly dangerous for patients on Anagrelide — more so than for many other chronic medications.
Providers should proactively discuss contingency plans with patients, including:
Generic Anagrelide is therapeutically equivalent to brand Agrylin and is significantly more available and affordable. Unless there is a specific clinical reason to require the brand, prescribing generic Anagrelide — or ensuring DAW (Dispense as Written) codes allow substitution — can improve patient access.
Anagrelide is positioned as a second-line therapy for essential thrombocythemia per current guidelines, typically after Hydroxyurea intolerance or failure. With the SURPASS-ET trial demonstrating Ropeginterferon Alfa-2b (Besremi) superiority over Anagrelide as second-line therapy (published January 2026), the treatment algorithm for ET is actively evolving. Providers should consider the broader therapeutic landscape when selecting second-line agents.
While no formal nationwide shortage exists, the practical availability of Anagrelide varies significantly by pharmacy type and geography:
Large chains (CVS, Walgreens, Rite Aid) may not routinely stock Anagrelide due to low local demand. Patients often encounter "we need to order it" responses, which can mean 2-5 business day delays.
Often have more flexible wholesale sourcing relationships and may be more reliable for specialty medications. Worth recommending to patients as a primary or backup option.
Pharmacies affiliated with cancer centers or hematology practices typically maintain consistent Anagrelide inventory. These offer the most reliable access for patients on chronic therapy.
Insurance-affiliated mail-order services generally have stable supply but require advance planning for initial fills and dose changes.
Cost can be a significant barrier to access, particularly for patients without adequate insurance coverage:
For patients with financial barriers:
Several tools can help you and your staff manage Anagrelide access for your patients:
Medfinder offers a provider-facing tool for locating pharmacies with specific medications in stock. This can be particularly useful when patients call reporting they can't fill their prescription — your staff can quickly identify alternative pharmacies with Anagrelide available.
Monitor the FDA's Drug Shortage Database (accessdata.fda.gov) for any new shortage listings affecting Anagrelide. Setting up alerts can provide early warning of emerging supply issues.
The American Society of Health-System Pharmacists maintains a drug shortage resource center that often provides more granular detail on shortage causes, affected NDCs, and estimated resolution timelines.
The treatment paradigm for essential thrombocythemia is shifting, which has implications for Anagrelide prescribing and demand:
These developments suggest that while Anagrelide will remain an important therapeutic option, it may shift further toward a third-line role for some patient populations.
Anagrelide availability requires proactive management — particularly given the boxed warning around abrupt discontinuation. Building relationships with reliable specialty pharmacies, ensuring patients understand the importance of early refills, and maintaining familiarity with alternative therapies are all essential components of managing patients on this medication.
For real-time pharmacy availability data, direct your patients to Medfinder or use the provider tools to search for stock on their behalf. Proactive planning today prevents crises tomorrow.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
